Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine
| Autor: | Robert W. Sharpe, Darren Sigal, Alan Saven, Carol Burian |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Neoplasm Residual Time Factors Databases Factual medicine.drug_class Immunology Antineoplastic Agents Biochemistry Antimetabolite Gastroenterology Drug Administration Schedule Moxetumomab pasudotox Clinical Trials Phase II as Topic Internal medicine Humans Medicine Hairy cell leukemia Survivors Cladribine Aged Retrospective Studies Aged 80 and over Leukemia Hairy Cell Hematology business.industry Remission Induction Cell Biology Middle Aged medicine.disease Minimal residual disease Surgery Leukemia Treatment Outcome Female business Complete Hematologic Response medicine.drug |
| Zdroj: | Blood. 115:1893-1896 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2009-10-251645 |
| Popis: | Cladribine induces protracted remissions in patients with hairy cell leukemia (HCL). However, many long-term responders ultimately relapse. We sought to determine whether long-term complete responders subsequent to a single 7-day course of cladribine were without minimal residual disease (MRD) and potentially cured of HCL. From the 358-person Scripps Clinic cladribine database, we identified 19 patients in continuous and complete hematologic response (median age, 75 years; median time from diagnosis, 18 years; and median time from cladribine, 16 years). Nine of 19 (47%) patient samples had no evidence of residual disease; 7 of 19 (37%) samples had MRD; and 3 of 19 (16%) had morphologic evidence of HCL in hematoxylin and eosin–stained bone marrow sections. These results indicate that HCL is potentially curable after cladribine treatment. In addition, patients with MRD and even gross morphologic disease can live many years without manifesting hematologic relapses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|